Sunitinib is a tyrosine kinase inhibitor (TKI) inducing thyroid dysfunction, but the precise mechanism(s) involved remains to be explained, including a role of thyroid autoimmunity. The objective was to evaluate thyroid function, parameters of autoimmunity, and thyroid ultrasound findings in patients with metastatic cancer and normal thyroid function/autoimmunity before the initiation of Sunitinib therapy. This is a prospective, observational cohort study.
Titolo: | Thyroid dysfunction in patients with metastatic carcinoma treated with Sunitinib: is thyroid autoimmunity involved? |
Autori: | |
Data di pubblicazione: | 2015 |
Rivista: | |
Abstract: | Sunitinib is a tyrosine kinase inhibitor (TKI) inducing thyroid dysfunction, but the precise mechanism(s) involved remains to be explained, including a role of thyroid autoimmunity. The objective was to evaluate thyroid function, parameters of autoimmunity, and thyroid ultrasound findings in patients with metastatic cancer and normal thyroid function/autoimmunity before the initiation of Sunitinib therapy. This is a prospective, observational cohort study. |
Handle: | http://hdl.handle.net/11584/123384 |
Tipologia: | 1.1 Articolo in rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
Pani et al Thyroid 25_1255_2015.pdf | Articolo principale | versione editoriale | Administrator Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.